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Abstract
Many plant secondary metabolites exhibit some degree of biological activity in humans. It is a common observation that
individual plant-derived compounds in vivo are present in the nanomolar concentration range at which they usually fail to
display measurable activity in vitro. While it is debatable that compounds detected in plasma are not the key effectors of
bioactivity, an alternative hypothesis may take into consideration that measurable concentrations also reside in
compartments other than plasma. We analysed the binding of constituents and the metabolite d-(3,4-dihydroxy-phenyl)-c-
valerolactone (M1), that had been previously detected in plasma samples of human consumers of pine bark extract
Pycnogenol, to human erythrocytes. We found that caffeic acid, taxifolin, and ferulic acid passively bind to red blood cells,
but only the bioactive metabolite M1 revealed pronounced accumulation. The partitioning of M1 into erythrocytes was
significantly diminished at higher concentrations of M1 and in the presence of glucose, suggesting a facilitated transport of
M1 via GLUT-1 transporter. This concept was further supported by structural similarities between the natural substrate a-D-
glucose and the S-isomer of M1. After cellular uptake, M1 underwent further metabolism by conjugation with glutathione.
We present strong indication for a transporter-mediated accumulation of a flavonoid metabolite in human erythrocytes and
subsequent formation of a novel glutathione adduct. The physiologic role of the adduct remains to be elucidated.
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Introduction
Maritime pine bark extract is monographed in the United States
Pharmacopeia (USP) as a dietary supplement [1]. A standardized
pine bark extract that conforms with this monograph is derived
from of Pinus pinaster, Ait., (PycnogenolH, Horphag Research Ltd.,
UK). Procyanidins consisting of catechin and epicatechin moieties
of varying chain lengths represent approximately 65–75% of this
extract [2,3]. Other constituents are polyphenolic monomers,
phenolic or cinnamic acids and their glycosides. PycnogenolH
revealed diverse pharmacological actions in human trials, e.g. anti-
inflammatory and cardiovascular effects [3,4]. So far there is still
limited information on which compound(s) of the complex extract
are mainly responsible for the documented bioefficacy.
One critical point with plant extracts is always the bioavailabil-
ity of their constituents. Typically only low plasma concentrations
are found after ingestion of dietary polyphenols or plant extracts
[5]. In a pharmacokinetic study with single and multiple doses of
PycnogenolH we detected catechin, caffeic acid, ferulic acid, and
taxifolin in the nanomolar range in the plasma of human
volunteers [6]. We also found a maritime pine bark metabolite,
d-(3,4-dihydroxy-phenyl)-c-valerolactone (M1), in the plasma
samples. This metabolite is no constituent of the extract, but is
generated in vivo from the procyanidins’ catechin units through
multiple step reactions. This metabolite M1 has been also found in
urine samples [7–10].
We previously investigated the bioactivity of M1 and discovered
pronounced antioxidant activity as well as inhibitory effects upon
various matrix metalloproteinases [11] which was consistent with
the reported anti-inflammatory effects of the extract. However,
again the plasma concentrations of M1 were only in the
nanomolar range [6] which was too low to induce any effects in
vitro. Though it is possible that M1 is not the main mediator of
maritime pine bark extract’s bioefficacy it is also conceivable that
plasma is not the only compartment where M1 is present in vivo.
Previously, significantly higher recoveries of quercetin and
resveratrol were reported from whole blood compared to plasma
which suggests that the polyphenols are also distributed into the
cellular blood fraction [12]. Recently we observed pronounced
uptake of M1 into endothelial cells and monocytes/macrophages
in vitro. The uptake was decreased by phloretin, suggesting a
facilitated transport mechanism [13].
Though the partitioning of compounds into red blood cells has
received less attention than the plasma protein binding, erythro-
cytes constitute a significant compartment for distribution [14,15].
We recently analyzed the plasma protein binding of various
maritime pine bark polyphenols and observed pronounced
differences in the binding tendency [16]. While catechin and
taxifolin displayed protein binding close to 100%, low binding
around 30% was seen for M1 and its structurally related
metabolite M2 (d-(3-methoxy-4-hydroxy-phenyl)-c-valerolactone).
The purpose of the present investigation was to analyse the
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binding of selected PycnogenolH constituents and the metabolite
M1 to human erythrocytes to gain further insight into the
disposition of these compounds.
Materials and Methods
Chemicals and reagents
Ferulic acid, (6)-taxifolin, caffeic acid, p-coumaric acid,
glutathione, glutathione-S-transferase (EC 2.5.1.18), phloretin,
and 2,29-azobis(2-amino propane (AAPH), cytochalasin B from
Drechslera dematioidea, D (+)-glucose, ethylene glycol-bis(2-ami-
noethylether)-N,N,N9,N9-tetraacetic acid (EGTA), were all ob-
tained from Sigma-Aldrich (Taufkirchen, Germany). 4-(2-Hydro-
xyethyl)piperazine-1-ethanesulfonic acid (HEPES) was purchased
from Gerbu (Wieblingen, Germany). The metabolite M1 (d-(3,4-
dihydroxy-phenyl)-c-valerolactone) was synthesized by M. Rap-
pold as part of his diploma thesis [17]. Methanol (HPLC grade)
was obtained from Merck (Darmstadt, Germany), acetonitrile
(HPLC grade) was from Fisher Scientific (Schwerte, Germany).
Ultrapure Milli-Q water was used for all aqueous solutions. All
other chemicals were purchased from Sigma-Aldrich.
Buffers and human plasma/erythrocytes
The phosphate buffered saline (PBS, pH 7.4) consisted of
137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4 and 1.5 mM
KH2PO4. In case of incubation with erythrocytes the PBS buffer
was supplemented with 0.1% (m/V) glucose. The buffer used in
the AAPH assay (pH 7.4) consisted of 150 mM NaCl, 8.1 mM
Na2HPO4 and 1.9 mM NaH2PO4 and 0.05% (m/V) glucose.
Human plasma and packed red blood cells were obtained from
the blood banks of the University Hospital of Wu¨rzburg and of the
Bayerisches Rotes Kreuz, Mu¨nchen, Germany.
Distribution of a polyphenol mixture between human
plasma and erythrocytes
Packed red blood cells were washed twice with a threefold
volume of cold PBS buffer (8uC) and centrifuged for 5 min at
952 g (10uC). Cells were weighted and assuming a density of
1.114 g/mL [18] 1.67 g were mixed with 2.0 mL plasma to obtain
a hematocrit value of 0.43. The plasma contained a mixture of
1.3 mM caffeic acid, 80 mM ferulic acid, 6 mM taxifolin and 6 mM
metabolite M1. The chosen concentrations were based on
analytical considerations and previously also used for determina-
tion of plasma protein binding of these compounds [16]. In
parallel a control was prepared containing the polyphenols in
3.5 mL plasma without erythrocytes. The tubes were incubated at
37uC and samples of 250 mL erythrocytes/plasma or plasma,
respectively, were drawn and centrifuged at 952 g for 5 min
(10uC). 100 mL of the supernatant was mixed with 10 mL of the
internal standard p-cumaric acid, 40 mL 0.5 M hydrochloric acid
and 130 mL methanol. After centrifugation at 14,000 g for 15 min
(4uC) 20 mL were directly injected into the HPLC. In case of
inhibition experiments the erythrocytes were pre-incubated with
600 mM phloretin (445 mL of a stock solution of 20 mg phloretin
in 10 mL PBS buffer containing 0.01% DMSO) for 15 min and
the samples were subsequently treated as described above. The
erythrocyte/plasma partitioning ratio of the compounds was
determined based on the peak area ratios to the internal standard
as described by Yu et al. [19].
To ensure the cell vitality the percentage of haemolysed
erythrocytes was determined according to Salauze [20] by
photometric measurement of haemoglobin in plasma at 450 nm.
Plasma was used as blank and samples of the erythocytes/plasma
incubation were compared to completely haemolysed erythrocytes
obtained after one freeze-thaw cycle (280uC). The % haemolysis
was calculated from the absorption of the cell supernatant in
relation to the absorption of the totally haemolysed sample. In all
experiments the percentage of haemolysed erythrocytes was below
3% over the whole experimental period.
Uptake of M1 into human erythrocytes
Packed red blood cells were incubated with a threefold volume
of PBS buffer with 100 mM D-glucose for 30 min at 37uC and
centrifuged for 5 min at 2,000 g temperated to 4uC (Mikrofuge 22
R, Beckmann CoulterTM, Krefeld, Germany). Thereafter these
cell pellets were washed twice with the threefold volume of cold
PBS buffer (4uC) containing 100 mM D-glucose and centrifuged
for 5 min at 2,000 g (4uC). 43 mL of these packed glucose-
saturated cells were mixed with PBS buffer to obtain a hematocrit
of 0.043. The cells were subsequently incubated with various
concentrations of M1 (0.3–10 mM) for 1 min by rocking (Mini
Rocker MR-1, Hartenstein, Wu¨rzburg, Germany) in closed
reaction tubes (Eppendorf, Hamburg, Germany) at room temper-
ature. In parallel control experiments were carried out accordingly
for each variable without cells to monitor the stability of M1
during the experimental procedures. Similar to the procedure
described by Leitch and Carruthers [21] the reaction was
interrupted by adding a cold stop solution (4uC) containing
150 mM KCl, 5 mM MgCl2, 5 mM EGTA, 5 mM HEPES,
20 mM cytochalasin B and 200 mM phloretin in PBS buffer
(pH 7.4), followed by a centrifugation of the cell preparations and
matched controls for 5 min at 2,000 g (4uC). The supernatants
were harvested and immediately analyzed by HPLC.
In case of competition experiments the erythrocytes were
glucose-deprived. Cells were washed twice with the threefold
volume of cold PBS buffer (4uC) without D-glucose and
centrifuged for 5 min at 2,000 g (4uC). After incubating the cells
with a threefold volume of PBS buffer (without D-glucose) for
30 min at 37uC and centrifugation for 5 min at 2,000 g (4uC), they
were washed twice with the threefold amount of cold PBS buffer
(4uC; without D-glucose) again and centrifuged for 5 min at
2,000 g (4uC). Subsequently, samples and controls were treated as
described above, but this time in addition with 100 mM D-glucose
to the various concentrations of M1 (0.3–10 mM). The erythro-
cyte/buffer partitioning ratio, or rather distribution coefficient, of
M1 was determined based on the peak area ratios to the internal
standard as described by Yu et al. [19].
In order to ensure equivalent cell counts in the experiments with
glucose-saturated and glucose-deprived cells (competition experi-
ments) the UV/VIS-absorption of free hemoglobin was measured
in the supernatant after cell lysis. Therefore, the incubation
mixtures with a hematocrit of 0.043 were prepared exactly as
described above. In case of experiments with glucose-saturated
erythrocytes (without D-glucose in the subsequent incubation)
43 mL of these cells were mixed with 957 mL PBS buffer.
Simultaneously, 43 mL of glucose-deprived cells prepared for the
competition experiments (with D-glucose in the subsequent
incubation) were mixed with 100 mM D-glucose in PBS buffer
to yield 1.0 mL. Then the samples were vortexed and snap frozen
in liquid nitrogen for 2 min. After 15 minutes of thawing at 37uC
the cells were centrifuged for 5 min at 2,000 g (4uC). A defined
volume of each supernatant was diluted and transferred into a 96-
well plate (BD falconTM clear 96-well microtestTM plate, Franklin
Lakes, NJ, USA) for subsequent photometric measurement of
hemoglobin. The absorption was measured at 450 nm (Multiskan
AscentH microplate-reader, Thermo Fisher Scientific, Waltham,
MA, USA). We prepared and measured each six independent
samples of both incubation conditions.
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High performance liquid chromatography (HPLC)
High performance liquid chromatography was performed using
a Waters HPLC (Milford, MA, USA) with a 1525 binary pump, a
717plus autosampler, a model 2487 UV/VIS dual wavelength
absorbance detector set at the detection wavelength of 280 nm.
Data collection and integration were accomplished using Bree-
zeTM software version 3.30.
Method 1: The samples of the experiments elucidation the
distribution of a polyphenol mixture between plasma and
erythrocytes were analysed by HPLC with a combination of
electrochemical and UV detection. Analysis was performed on a
Zorbax SB C8 column (150 6 4.6 mm I.D., 5 mm particle size,
Agilent Technologies, Palo Alto, CA, USA). Caffeic acid, M1 and
(6)-taxifolin were analyzed by electrochemical detection (CLC
100; Chromsystems, Munich, Germany) using oxidation voltage of
0.5 V. Ferulic acid was analyzed by UV detection (280 nm); this
detector was connected to the control system by a satellite interface
(Waters). The flow rate was 1 mL/min, the injection volume
20 mL. Isocratic elution was performed using 88% aqueous phase
(containing 0.6 mM 1-octanesulfonic acid sodium salt, 0.27 mM
ethylenediaminetetraacetic acid disodium salt, 0.04 M triethyl-
amine; pH 2.95 adjusted with phosphoric acid) and 12%
acetonitrile. The method was validated according ICH guidelines.
The method fulfilled the quality criteria for linearity, selectivity
and intra- and inter-day precision.
Method 2: The samples of the experiments elucidation the
uptake of M1 into human erythrocytes were analysed by HPLC
with UV detection similar to the method described previously
[13]. Therefore, samples were mixed with 0.6 mM p-coumaric
acid as internal standard and 50 mL of 50% solution of
trichloroacetic acid, vortexed for 10 s and centrifuged for
15 min at 18,000 g (4uC). Afterwards, 200 mL of the supernatant
was immediately subjected to HPLC analysis. Separations were
carried out on a SunFireH C18 column (4.6 x 150 mm; 5 mm
particle size) from Waters. The mobile phase consisted of 0.2% (v/
v) acetic acid and acetonitrile. Isocratic elution of M1 and internal
standard was performed using 85% aqueous phase and 15%
acetonitrile at a flow rate of 1.5 mL/min followed by a short flush
step for eluting remaining matrix components. M1 and internal
standard absorption was monitored at 280 nm. Retention time for
M1 was tR= 7.1060.08 min and for internal standard p-coumaric
acid tR= 9.5860.09 min. Linearity was proven between 0.15–
10 mM M1 in PBS buffer (r2 = 0.9999; slope = 0.270860.021; y-
intercept = 0.018960.016) analyzing five concentration levels.
The lower limit of quantification for M1 in PBS buffer was
0.15 mMM1 with VK (coefficients of variation) values for accuracy
of 99.4% and precision of 24.3%. Interday-accuracy and –
precision VK-values for M1 were 100.2% and 10.8% and
intraday-accuracy and –precision VK-values comprised 96.0%
and 7.9%.
Computer-based structural comparison between glucose
and M1
Calculations were made with the program SYBYL-XH (Tripos,
version 1.0, August 2009). An energy field minimization was
performed for the structures of glucose and M1 using the Powell
method. Electrical charges and the resulting energy were
calculated with MMFF94 taking various partial energies into
account such as bond stretching, angle bending, torsional and Van
der Waals energy. The energy-minimized molecules were used for
alignments.
Screening of erythrocyte incubation mixtures for
putative M1 metabolites
About 5 mL of packed red blood cells were washed twice with a
threefold volume of cold PBS buffer (8uC) centrifuged for 5 min at
952 g (10uC). Cells were suspended in PBS buffer to yield a cell
fraction of 40%. The metabolite M1 was added to yield a
concentration of 15 mM and cells were incubated for one hour at
37uC. In parallel a control was prepared containing M1 PBS
buffer without erythrocytes. Cells were subsequently processed as
described by Sana et al. [22]. Therefore, incubation vials were
centrifuged at 1,000 g (4uC) and erythrocytes were lysed by
addition of 150 mL cold MilliporeH water. Lysates were cooled on
dry ice to 225uC and 600 mL cold methanol was added. After
vortexing and addition of 450 mL chloroform, samples were
incubated for 30 min under frequent mixing. Another 150 mL cold
MilliporeH water was added and samples were frozen at 220uC
for at least 8 hours. Both the upper aqueous and lower organic
phase were collected and evaporated to dryness. The residue was
reconstituted in 50 mL mobile phase of which 5 mL were subjected
to HPLC-MS/MS analysis.
Preparation of a M1-glutathione conjugate
Glutathione (10 mM) and the metabolite M1 (12 mM) were
mixed with 1 U glutathione-S-transferase in 1 mL PBS buffer. The
mixture was incubated for 30 min at 25uC. The MS/MS
spectrum of the reaction product was compared with the putative
glutathione adduct found in erythrocytes.
HPLC-MS/MS conditions
High-performance liquid chromatography-MS/MS analyses
were performed on an Agilent LC-MS 6460 triple-quadrupole
mass spectrometer with an electrospray interface (Agilent,
Bo¨blingen, Germany). Chromatographic separations were carried
out using an SunFireH C18 column (4.6 x 300 mm, 2.5 mm
particle size with a guard column; Waters) at a flow rate of
0.5 mL/min using 0.1% formic acid in MilliporeH water (solvent
A) and acetonitrile/methanol 1:1 (solvent B) as mobile phase. A
linear step gradient elution was performed: 95% to 10% solvent A
in 40 min, followed by 100% B for 10 min. During screening, the
electrospray interface source was operated in both the positive and
negative ionization mode for later measurements of metabolites
only the positive ionization mode (ESI+) was used at a capillary
voltage of 3.50 kV and a desolvation temperature of 300uC.
Detection was performed using multiple reaction monitoring
(MRM) mode. The scan range used was 100–1000 m/z with a
step size of 0.2 Da. Nitrogen was used as the desolvation and
sheath gas with flow rates of 11 L/min, respectively. Nitrogen was
used as the collision gas at a pressure of 45 psi. Data were analyzed
using Agilent MassHunter data aquisition version B 02.01.
Analysis of protection against oxidative damage using
the AAPH assay
About 3 mL of the packed red cells were washed twice with
10 mL of the AAPH buffer and subsequently mixed with the
AAPH buffer to result in a 10% (V/V) suspension. 12.0 mL
buffer containing 1 mM of the metabolite M1 were mixed with
1.5 mL of the erythrocyte cell suspension and incubated under
gentle shaking for 10 min at 37uC. 1.5 mL of AAPH solution
(400 mM) was added either immediately or after pre-incubation
of the cells with M1 for 60 min at 37uC. Subsequently samples of
800 mL were drawn and centrifuged for 2 min at 10,000 g at
4uC. The absorption of the supernatant was measured at 524 nm
(uv-mini 1240, Shimadzu, Duisburg, Germany). For comparison
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a completely haemolysed sample was used. Therefore, 10 mL of
the packed red cells were mixed with 990 mL of MilliporeH water
and subjected to one freeze-thaw cycle. The % haemolysis was
calculated from the absorption of the cell supernatant in relation
to the absorption of the totally haemolysed sample. The time lag
for a 50% haemolysis occurred was determined.
Statistical and data analysis
Data sets were subjected to one-way analysis of variance
(ANOVA) with Bonferroni’s multiple comparison test using
GraphPad PrismH 4 (GraphPad Software Inc., Dan Diego, CA).
Results were considered statistically significant at p#0.05. Data
are shown as mean with standard deviation (SD) or as mean and
mean deviation of the mean (MDM).
Results
Distribution of polyphenols between human plasma and
erythrocytes
The erythrocyte/plasma partitioning ratio of a mixture of
caffeic acid, taxifolin, ferulic acid and the PycnogenolH metab-
olite M1 (d-(3,4-dihydroxy-phenyl)-c-valerolactone) was deter-
mined based on a previously described method [19]. While all
compounds displayed some binding to the erythrocytes after
60 min this effect was no longer pronounced after 120 min for
caffeic acid, taxifolin, and ferulic acid (Figure 1). In contrast, the
binding of M1 to red blood cells increased further to result in an
erythrocyte/plasma partition ratio of 32.8364.65 after 120 min
and remained at 37.36610.13 until 350 min.
To elucidate whether this high partition coefficient of M1 was
not only related to an adsorption to erythrocytes’ outer cell
membrane and diffusion processes, but to an entry and
accumulation in the cells we tested the influence of various
inhibitors of transporters that facilitate the uptake of small
molecules into red blood cells. While no significant effects were
seen with modulators of the ABCB1 (P-glycoprotein) and amino
acid transporters (data not shown) a statistically significant
decrease (p,0.05, one-way ANOVA with post-hoc Bonferroni
test) of M1 uptake into erythrocytes was observed after 10 min in
the presence of the inhibitor phloretin that e.g. inhibits the
glucose transporters (GLUT-1) (Figure 2). In the presence of
phloretin the erythrocyte/plasma partitioning ratio of M1
displayed a mean value of 1 while the partition coefficient
increased up to 2.4761.28 after 10 min in the absence of
phloretin.
Uptake of M1 into human erythrocytes
To elucidate whether the high partition coefficient of M1 was
solely due to an adsorption to erythrocytes’ outer cell membrane,
diffusion processes, or the presence of other polyphenolic
compounds we determined the distribution of M1 in separate
experimental series. In initial experiments we analyzed the
uptake of increasing concentrations of M1 (0.3 to 1 mM) into red
blood cells. When we added inhibitors of glucose transporters
(200 mM phloretin and 20 mM cytochalasin B) to stop a potential
facilitated uptake we observed clearly reduced distribution
coefficients (Figure 2). Likewise, the concomitant addition of
100 mM glucose along with M1 resulted in reduced uptake of
M1. In this case, the addition of the stop solution at the end of
the incubation period again reduced the distribution coefficient.
Further experiments were performed in which the stop solution
containing phloretin and cytochalasin B was always added to
terminate any transporter-facilitated uptake. Erythrocytes of two
different individuals (blood groups A and AB, respectively) were
used for the experiments. The results differed only slightly, so that
the data were pooled (Figure 3). In the absence of glucose,
increasing concentrations of M1 resulted in decreasing distribution
coefficients, from 24.6863.68 (0.3 mM M1) to 4.8761.97 (10 mM
M1). Thereby, the distribution coefficients determined for 0.3, 0.6
and 1 mM M1 were statistically significant higher compared to
that recorded for 10 mM M1 (p,0.001; one-way ANOVA with
Bonferroni post-hoc test). When 100 mM glucose was added to the
red blood cells together with M1, the distribution coefficients were
clearly lower, ranging from 15.4861.96 (0.3 mM M1) to
4.6660.57 (10 mM M1). For the concentrations of 0.3, 0.6 and
1 mM M1 the uptake into erythrocytes was statistically significant
higher in absence of glucose compared to the respective M1
concentrations added simultaneously with glucose (p,0.05; one-
way ANOVA with Bonferroni post-hoc test). At a concentration of
10 mM the distribution coefficient of M1 was not different in the
absence or presence of glucose.
In order to exclude the possibility that the cells’ exposure with
high glucose concentrations altered the cell volume and thus the
cell number that constituted the hematocrit, we prepared each six
independent samples of both incubation conditions, lysed the
erythrocytes and measured the absorption of the free hemoglobin
in the supernatant (l=450 nm). We read absorptions of
0.846360.036 (n= 6; mean and SD) and 0.798360.083 (n= 6;
mean and SD) which were not statistically significant different
(p.0.05, two-sided Student’s t-test).
Structural comparison between M1 and glucose
Structural similarities between M1 and the natural GLUT-1
substrate a-D-glucose were analysed using computer-based energy
calculations. Molecule alignments showed good superimposing
substructures between glucose and the S-isomer of M1 (Figure 4).
The hydroxyl groups of the benzene ring of M1 aligned well with
the hydroxyl function of the pyranose ring and the hydroxymethyl
moiety of glucose aligned close to the lactone structure of M1.
Thus, functional groups such as OH-groups that might be critical
for the transport through the GLUT uptake site can adopt similar
positions in the three-dimensional space. Both molecules have
similar space requirements, there are no obvious steric or volume
hindrances that would suggest that M1 cannot pass through the
GLUT transporter.
Figure 1. Erythrocyte/plasma partitioning ratios of polyphe-
nols. 1.3 mM caffeic acid, 6 mM taxifolin, 80 mM ferulic acid and 6 mM of
the Pycnogenol metabolite M1 were concomitantly incubated with a
human blood mixture (hematocrit 0.43) at 37uC. Each data point
represents the mean and standard deviation of five replicates.
doi:10.1371/journal.pone.0063197.g001
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Screening of erythrocyte incubation mixtures for
putative M1 metabolites
To screen for potential metabolites of M1 generated in human
erythrocytes the compound was incubated with red blood cells and
subjected to an extraction procedure that allowed the determina-
tion of both hydrophilic and lipophilic metabolites [22]. The
extracts were scanned by LC-MS/MS in both the positive and
negative ionisation mode over a range of 100–1000 m/z with a
step size of 0.2 Da. For comparison an erythrocyte extract that was
not exposed to M1 was used. During this screening procedure a
new signal with [M+H]+ m/z of 514 was detected (Figure 5, A).
This molecular mass was consisted with a glutathione adduct of
M1. To obtain a reference compound M1 and glutathione were
incubated in the presence of glutathione-S-transferase and the
resulting MS/MS spectrum of the reaction product was analysed
(Figure 5, B). Besides the signal with [M+H]+ m/z of 514
fragments described to be characteristic for glutathione such as
pyrroglutamic acid [MH+-129], cysteine [MH+-103] and glycine
[MH+-76] [23,24] were detectable.
Figure 2. Influence of the stop solution on the uptake of M1 into human erythrocytes. In an initial experiment the distribution of different
concentrations of the metabolite M1 was analyzed in the absence and presence of glucose (100 mM) with and without addition of a stop solution
containing phloretin (200 mM) and cytochalasin B (20 mM). Data points of the experiments with stop solution (solid lines) represent the mean and
mean deviation of the mean of three replicates, the data points without stop solution (dashed lines) were single experiments.
doi:10.1371/journal.pone.0063197.g002
Figure 3. Distribution of M1 into human erythocytes. Increasing concentrations of the metabolite M1 were incubated in the absence and
presence of glucose (100 mM) with human erythrocytes (hematocrit 0.043) at 4uC. The reaction was stopped after one minute with phloretin
(200 mM) and cytochalasin B (20 mM). For 0.3 to 1 mM M1 the uptake into erythrocytes was statistically significant higher in absence of glucose
compared to the respective uptake (0.3 to 1 mM M1) in the presence of glucose (p,0.05) and also compared to the uptake of 10 mM M1 (p,0.001;
one-way ANOVA with Bonferroni post-hoc test). Each data point represents the mean and mean deviation of the mean of six replicates.
doi:10.1371/journal.pone.0063197.g003
Uptake of a Bioactive Metabolite into Erythrocytes
PLOS ONE | www.plosone.org 5 April 2013 | Volume 8 | Issue 4 | e63197
Analysis of protection against oxidative damage using
the AAPH assay
To elucidate whether the red blood cell bound M1 or its
glutathione adduct conferred a different degree of the erythro-
cytes’ protection against oxidative damage an AAPH assay was
performed. Therefore, erythrocytes M1 was either directly added
to the incubation mixture or pre-incubated with the red blood cells
for 60 min to allow for M1 uptake and metabolism. Subsequently
the delay of 50% haemolysis was determined with reference to an
incubation mixture without addition of M1 (Figure 6). The more
pronounced delay of induced haemolysis was seen when M1 was
freshly added to the incubation mixture (Dt of 23.169.6 min)
compared the pre-incubation conditions (Dt of 7.47610.8 min).
Discussion
In the present investigation we analyzed the distribution of
polyphenols into human red blood cells and found a strong
indication for a facilitated uptake and accumulation of the
Pycnogenol metabolite d-(3,4-dihydroxy-phenyl)-c-valerolactone
(M1) in erythrocytes. The partitioning of M1 into erythrocytes was
significantly diminished at higher concentrations of M1, in the
presence of glucose and upon the addition of a transporter-
inhibiting stop solution containing phloretin and cytochalasin B.
This is suggestive of a facilitated uptake of M1 into red blood cells,
possibly via GLUT-1. This notion was further supported by
structural similarities between the natural GLUT-1 substrate a-D-
glucose and the S-isomer of M1. Erythrocytes metabolize M1 to
form a novel glutathione adduct which role needs to be further
investigated.
Many plant extracts used as phytotherapeutics or dietary
supplements exhibit bioactivity [4,25] while plasma concentrations
of individual compounds are typically in the nanomolar range
[5,6]. However, these low concentrations are usually not sufficient
to exert any measurable activity in in vitro cell culture assays
[11,26]. It is possible that either the compounds detected in
plasma are not the key effectors of bioactivity or that measurable
concentrations also reside in compartments other than the plasma.
It has been shown that the recoveries of resveratrol and quercetin
were significantly higher from whole blood compared to plasma
[12]. We recently found a pronounced binding of M1 to
endothelial cells and monocytes/macrophages which was de-
creased in the presence of phloretin, suggesting a facilitated uptake
[13].
Red blood cells represent more than 99% of the total cellular
space of human blood and can thus constitute a significant
compartment for distribution. Various drugs and endogenous
compounds bind to erythrocytes [15]. Red blood cells were shown
to bind polyphenols, and gallic acid, curcumin and resveratrol
were most extensively bound [27]. Erythrocyte/plasma partition-
ing ratios higher than 0.25 indicate association of the respective
compound with red blood cells, which could be either an uptake
into the cells or binding to the surface membranes [15]. In our
experiments with a polyphenol mixture all compounds revealed
higher red blood cell/plasma partitioning ratios than 1.0 up to
60 min. Afterwards the partition coefficients of caffeic acid,
taxifolin and ferulic acid decreased. In contrast, the erythrocyte/
plasma partitioning ratio of M1 increased further to over 30
remained at that high level up to 350 min. This is suggestive of an
accumulation of M1 within or on the surface of red blood cells.
It has been discussed that the compound’s lipophilicity is a
major determinant for its distribution in the body [15]. Indeed, in
an analysis of whole blood compared to analysis of plasma it
appeared that the more lipophilic resveratrol was bound to a
higher extent to blood cells compared to quercetin [12]. However,
in the present study we did not observe any correlation between
the compounds’ lipophilicity and the binding to erythrocytes, just
as we previously did not find a correlation of the polyphenols’
lipophilicity or topological polar surface area with plasma protein
binding or nonspecific binding to material surfaces [16]. Especially
the high binding of M1 to erythrocytes was striking since its
plasma protein binding is significantly lower compared to caffeic
acid, taxifolin and ferulic acid. We suspected that the accumula-
tion of M1 in erythrocytes was not solely driven by diffusion
processes.
When we determined the binding of M1 alone we found high
uptake into human red blood cells already after one minute and a
statistically significant decrease of the distribution coefficient with
increasing concentrations. The simultaneous addition of M1 and
glucose to erythrocytes significantly reduced the uptake of M1 at
lower concentrations (0.3–1 mM), but no further decrease was seen
at the highest tested concentration of 10 mMM1. These results are
consistent with a transporter-facilitated uptake and a substrate
inhibition at higher M1 concentrations. Since erythrocyte glucose
transport is facilitated by GLUT-1 transporter which is highly
expressed in these cells, accounting for 10% of the total protein
mass [28,29], it appears most likely that M1 is taken up via this
transport system as well. Another indication for this notion is that
the addition of a stop solution containing phloretin and
cytochalasin B at the end of the incubation period clearly reduced
the distribution coefficient of M1. Both phloretin and cytochalasin
B are inhibitors of GLUT-1 transporters [30] although they are
not highly selective. Phloretin for example interacts with various
transporters such the monocarboxylate transporter [31], sodium
glucose co-transporter SGLT-1 [32], volume-sensitive chloride
channels [33], aquaporin water channels [34] or the red blood cell
urea transporter [35]. Though phloretin also binds to other
GLUT isoforms [36] it potently inhibits the GLUT-1-type glucose
transporter [37].
Besides the facilitating the uptake of glucose into red blood cells
GLUT-1 also transports other molecules such as galactose,
mannose, L-dehydroascorbic acid (DHA) and tyrosine [38–40].
Interestingly, compounds such as DHA can be taken up into
human erythrocytes although they are present at a significantly
lower concentration in plasma compared to glucose. It has been
suggested that the GLUT-1 uptake profile might be modulated by
Figure 4. Structural alignments of M1 and glucose. The S-isomer
of the metabolite M1 (d-(3,4-dihydroxy-phenyl)-c-valerolactone; blue)
and glucose (yellow). The calculations were performed with SYBYL-XH
(Tripos, version 1.0).
doi:10.1371/journal.pone.0063197.g004
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Figure 5. MS/MS spectra of the M1-glutathione adduct. A: MS/MS spectrum of the putative M1-glutathione adduct with [M+H]+ m/z of 514
found in the erythrocyte lysate after incubation with the metabolite M1. B: MS/MS spectrum of the M1-glutathion adduct with [M+H]+ m/z of 514
obtained after incubation of the metabolite M1 with glutathione and glutathione-S-transferase. Characteristic fragments for glutathione are
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GLUT binding partners such as stomatin [41,42]. Association of
GLUT-1 with stomatin was shown to decrease glucose uptake and
enhance DHA uptake [41–43]. While we did not investigate any
mechanistic background we also observed that M1 was taken up
by human erythrocytes in the presence of an excess concentration
of glucose.
Recently docking studies have shown that besides a-D-glucose
also quercetin might slide through the GLUT-1 transporter [44],
thus suggesting that this transporter accepts structurally variable
molecules. Structural comparisons between a-D-glucose and the
S-isomer of M1 revealed good alignment which further supports
the notion that a facilitated uptake of M1 into erythrocytes might
be possible since there are no obvious structural restrictions that
make it unlikely that M1 can pass through the GLUT transporter.
So far it is not clear yet which M1 isomer predominantly occurs in
vivo. Though a preferred excretion of one isomer has been
described [9,10] the designation as ‘‘–’’ isomer does not allow to
deduce whether this is the R- or S-isomer according to CIP
nomenclature.
The significance of partitioning of drugs into red blood cells has
been detailed earlier [14,15]. The distribution into erythrocytes
contributes to the storage, transport and metabolism of molecules
and may affect their activity [45]. The elimination half-life of
compounds from different blood constituents might vary, the
discharge from erythrocytes is often faster than the loss from
plasma proteins so that red blood cells constitute a transport
system with high capacity and low affinity compared to plasma
proteins [14]. However, it is also known that the half-life of a
compound can be longer in erythrocytes compared to the plasma
half-life, e.g. for methotrexate [45].
Due to an enhanced uptake of M1 into red blood cells the total
presence of this compound in vivo might be overall higher than
previously deduced from its plasma concentrations [6]. It can be
speculated that an enhanced uptake of M1 will also seen in other
tissues that express GLUT-1, such as the blood-brain barrier [46].
Furthermore it is possible that the transport in or on red blood
cells facilitates an efficient exchange of the compound between the
erythrocyte and the capillary endothelium [14].
After partitioning into red blood cells compounds might be
subjected to intracellular metabolism. This has been described for
many drugs and also for endogenous molecules [15,45]. Thus,
after observing an accumulation of M1 in human erythrocytes we
screened the cell lysates for potential metabolites and identified a
M1 glutathione conjugate. Red blood cells contain 200–400 mg
glutathione per mL blood [47] and possess a glutathione-S-
transferase [48]. Formation of glutathione adducts has been
described as part of detoxification of xenobiotics [49]. Recently it
has been described that glutathione adducts with flavonoids, e.g.
quercetin, are formed after scavenging of free radicals and
formation of electrophilic quinones [50,51]. M1 also displays
structural features that allow oxidation under formation of an
electrophilic benzoquinone that would be preferentially attacked
at C4 by the nucleophilic thiol moiety of glutathione. However,
this is not supported by the MS/MS spectrum of the M1-
glutathione adduct with [M+H]+ m/z of 514 which is not
consistent with formation of a quinone. Glutathione conjugation
is a reversible process for certain compounds, e.g. for quercetin
[50,52,53]. However, we did not investigate whether the M1
adduct formation is a reversible process and the precise role of the
glutathione conjugate still needs to be clarified.
Quercetin and other polyphenols were reported to inhibit
oxidative haemolysis of red blood cells [27,54]. We previously
demonstrated in various assays that the Pycnogenol metabolite M1
is a potent radical scavenger [11]. We now analysed whether a one
hour pre-incubation and thus accumulation and conjugate
formation of M1 in erythrocytes changed the resistibility of the
cells against oxidative haemolysis. The protection against haemo-
lysis was less pronounced after pre-incubation compared to direct
addition of M1 to the erythrocyte incubation mixture. It can be
concluded that M1 confers protection against oxidative stress
primarily if present outside the cell. This is consistent with the
results of Koren et al. [27] who found that the polyphenols bound
the erythrocytes’ surface form antioxidant depots and protect
against oxidative stress.
Our study has a number of limitations. The initial experiments
were done with mixtures of all polyphenols and it is possible that
the partitioning behaviour of individual compounds influenced the
partitioning of others, e.g. by inhibiting a relevant transporter
system. However, we think that the significant decrease of M1
uptake into erythrocytes at higher concentrations of this metab-
olite as well as in the presence of glucose support our notion of an
enhanced uptake of M1 into red blood cells. The intracellular
presence of M1 was also confirmed by the detection of a
glutathione conjugate. We did not elucidate the extent of
glutathione adduct formation compared to M1 uptake into red
blood cells or whether an enhanced outward transport of the
glutathione conjugate or a reverse of the conjugation reaction
occurred. Thus, we do not know whether the presence of M1 in
erythrocytes is altered due to its metabolism. Finally, it is possible
that M1 is taken up into erythrocytes by a transporter other than
GLUT-1. However, the high abundance of GLUT-1 transporters
in red blood cells [28,29] and the structural similarity of M1 and
the natural GLUT-1 substrate glucose suggest an involvement of
GLUT-1. Yet it cannot be excluded that additional diffusion
processes play a role as it was suggested by Sugano et al. that
passive and carrier-mediated processes can coexist [55]. Finally,
we did not investigate whether the glucose flux in erythrocytes was
influenced by M1 or the precise type of interaction with the
GLUT-1 transporter. Kinetic and mechanistic details of the
erythrocyte glucose transport are still ascertained [21,56]. While
GLUT-1 has binding sites for polyphenols such as quercetin or
pyrroglutamic acid [MH+-129], cysteine [MH+-103] and glycine [MH+-76] are present.
doi:10.1371/journal.pone.0063197.g005
Figure 6. Protection of erythrocytes against oxidative haemo-
lysis in the presence of M1. Haemolysis of a 1% human erythrocytes
suspension in the presence of the metabolite M1 (1 mM) was
determined in an AAPH-assay. Erythrocytes were either co-incubated
with M1 (left column) or pre-incubated with M1 for 60 min (right
column), and delay of haemolysis was determined with reference to an
incubation mixture without addition of M1. Columns represent the
mean and standard deviation of three replicates.
doi:10.1371/journal.pone.0063197.g006
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phloretin the type of interaction with the transporter appears to be
complex as compounds can behave as competitive or noncom-
petitive inhibitors regarding glucose uptake or exit [30]. Though
we do not provide further details on the transport of M1 we
uncovered a novel disposition site for this bioactive compound of
plant origin.
To summarize, we found that caffeic acid, taxifolin, ferulic acid,
and M1 all bind to human erythrocytes, but only the Pycnogenol
metabolite M1 revealed accumulation within the cells. The more
than 30-fold increase in the erythrocyte/plasma partitioning ratio
indicates that red blood cells are a significant compartment for
distribution of M1. M1 was previously shown to exert pronounced
anti-inflammatory activities [11], but the plasma concentrations
were rather low in the nanomolar range [6]. Our present results
thus substantiate that low plasma concentrations do not necessarily
reflect low presence of the compound in vivo. The uptake of M1
into erythrocytes was diminished in the presence of glucose and at
higher concentrations of metabolite itself, suggesting a facilitated
uptake of M1 into red blood cells, possibly via GLUT-1. In
erythrocytes an intracellular conjugation of M1 yielding a
glutathione adduct was detected, but the precise role of the
reaction needs to be further investigated. Thus, we present novel
data on the disposition of the bioactive maritime pine bark extract
metabolite M1. This might help to further understand the in vivo
behaviour of plant extract components.
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